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1. Introduction
Term and preterm parturition have a common pathway that includes irregular uterine
contractions, cervical effacement and dilatation, along with decidual activation and rupturing
of the chorioamniotic membrane. This pathway is observed in the physiologic labor at term as
well as in the pathological processes leading to premature delivery. Indeed, the clinical
presentation of preterm parturition involves all components of this common pathway: 1.
Preterm contractions in women with spontaneous preterm labor with intact membranes;
2.cervical effacement and dilatation in women with cervical insufficiency; and/or 3.decidual
activation and rupture of membranes in those with preterm PROM.
The syndrome of preterm parturition is the clinical presentation of several underlying
mechanisms, not all of them being fully understood. Among the well establishes etiologies for
preterm parturition are: intra amniotic infection/inflammation, cervical insufficiency, in‐
creased thrombin generation and vascular pathology of the placenta, as well as multiple
gestations. The study of the maternal fetal interface and the placenta contributes to the
deciphering of the mechanism leading to preterm birth. Placental and decidual vascular lesions
have been reported in about 20-30% of patients who deliver preterm. There are accumulating
evidence that preterm parturition is associated with an increased activation of maternal
hemostatic system which also interacts with the acute inflammatory processes observed in this
syndrome. Moreover, higher rates of fetal growth restriction and placental vascular lesions
were observed among women with preterm labor who delivered at term suggesting that some
vascular insults may not be severe enough to cause preterm birth but still inflict some effect
on fetal growth.
© 2013 Klaitman et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The following chapter will summarize the changes in maternal hemostatic system during
normal pregnancy and those associated with preterm labor and preterm PROM. In addition,
we will review the vascular changes associated with preterm parturition. The last section of
this chapter will address the role of the hemostatic and angiogenic markers for the prediction
of spontaneous preterm birth.
2. The physiology of hemostasis
Hemostasis is crucial for the maintenance of the vascular tree integrity.
The major components of the hemostatic system, which function in concert, are the following:
1) the vessel wall and endothelium; 2) platelets and other formed elements of blood, such as
monocytes and red cells; and 3) plasma proteins (the coagulation and fibrinolytic factors and
inhibitors). These components act altogether in a synchronize fashion to generate the hemo‐
static plug, preserve the integrity of the vascular tree in the body, and avoid uncontrolled clot
formation and thrombosis (See figure 1).
Figure 1. Initiation of coagulation by endothelial injury and exposure of tissue factor to the extrinsic pathway. Then,
the platelets aggregate by activation of intrinsic pathway and platelet activation. And finally propagation and clot sta‐
bilization by thrombin – fibrin balance formation (from reference #12 with permission).
The vessel wall: Endothelial damage or activation is a crucial event that launches the cascade
of reactions leading to thrombin generation and fibrin clot formation. The vascular endothe‐
lium is the focal point for both initiation and inhibition of the coagulation process. During
endothelial damage the sub endothelial tissue factor molecules are exposed and initiate
coagulation by activation of the extrinsic pathway. This is relevant also for the maternal fetal
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interface since the villous and exteravillos trophoblast of the human placenta adopt the
properties of endothelium and vessel wall in order to allow laminar flow of maternal blood
through the placental bed without unnecessary activation of the coagulation cascade; and any
damage in their integrity will activate the coagulation cascade.
Platelets activation and plaque formation: Following vascular injury platelets initially adhere
to sub-endothelial collagen via von Willebrand factor (vWF) (figure 2). These vWF ‘‘bridges’’
are anchored at one end to sub-endothelial type IV collagen molecules and at the other end to
the platelet GPIb/IX/V receptor [1,2]. The adherent platelets can also attach to other sub-
endothelial extracellular matrix proteins (e.g. laminin, fibronectin, and vitronectin) via cell-
membrane bound integrins [3]. The binding of these receptors activates the platelets through
calcium-dependent cytoskeletal changes.
Figure 2. Mediators of platlet activation and agregation (from reference #5 with permission).
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Activated platelets form pseudopodia that further enhance vWF coupling to the sub endothe‐
lium. Moreover, ADP induces a conformational change in the GPIIb/IIIa receptor on the
platelet membrane causing platelet aggregation via the formation of a high affinity fibrinogen
bridges anchored at either end by GPIIb/IIIa receptors on 2 different platelets [4]. Thus, Platelet
activation converts the normally inactive Gp IIb/IIIa receptor into an active one, enabling
binding to fibrinogen and VWF. Because the surface of each platelet has about 50,000 Gp IIb/
IIIa-binding sites, numerous activated platelets recruited to the site of vascular injury can
rapidly form an occlusive aggregate by means of a dense network of intercellular fibrinogen
bridges. Since this receptor is the key mediator of platelet aggregation, it has become an
effective target for antiplatelet therapy [5].
2.1. Plasma proteins
Coagulation factors: Plasma coagulation proteins (clotting factors) normally circulate in plasma
in their inactive forms. The sequence of coagulation protein reactions that culminate in the
formation of fibrin was originally described as a waterfall or a cascade. Two pathways of blood
coagulation have been described in the past: the extrinsic, or tissue factor, pathway and the
intrinsic or contact activation, pathway (figure 3). However, the current approach is a more
unify view in which the coagulation cascade is normally initiated through tissue factor
exposure and activation of the extrinsic pathway that generates thrombin and activates the
elements of the classic intrinsic pathway. These reactions take place on phospholipid surfaces,
usually on activated platelets.
The initial phase of coagulation is the exposure of tissue factor to coagulation factors, caused ei‐
ther by endothelial damage or activation [6]. Tissue factor (TF) is a 47kDa cell bound trans-mem‐
brane glycoprotein and member of class 2 cytokine superfamily [7], that functions as: 1) a
receptor, with signal transduction resulting in the induction of genes involved in inflammation,
apoptosis, embryonic development and cell migration[8]; and 2])as an activator and cofactor for
factors VII/VIIa in the coagulation cascade. It is constitutively expressed by many extravascular
tissues, especially perivascular ones, and it is highly expressed in the brain, heart, lungs, kid‐
neys, testis and placenta [9-11], reflecting the importance of these tissues to the organism[12]. TF
expression can be induced in monocytes and platelets, and has been detected on circulating mi‐
croparticles (MP) derived from these and other cell types [7,13]. The expression of this coagula‐
tion factor can also be induced on endothelium in response to inflammatory stimuli including
exposure to: 1) bacterial lipopolysaccharide (LPS) in sepsis; 2) adhesion molecules (P-selectin
expressed on platelets, CD40 ligand expressed on white blood cells); and 3) inflammatory cyto‐
kines (interleukin- 6, tumor necrosis factor), and oxidized low-density lipoprotein(LDL) [14].
Tissue factor activates the coagulation cascade by binding to the serine protease factor VIIa;
the complex of TF+FVIIa activates factor X to factor Xa and initiating the converting factor IX
to factor IXa in the intrinsic system leading to further formation of factor Xa. Thus, this factor
is formed through the actions of either the tissue factor/factor VIIa complex or factor IXa (with
factor VIIIa as a cofactor), and converts pro-thrombin to thrombin, the pivotal protease of the
coagulation system. Thrombin is a multifunctional enzyme that converts soluble plasma
fibrinogen to an insoluble fibrin matrix. Thrombin also activates factor XIII (fibrin-stabilizing
factor) to factor XIIIa, which covalently cross-links and thereby stabilizes the fibrin clot.
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Figure 3. The extrinsic and intrinsic pathways of coagulation are a model for simplifying the coagulation system. This
model is reflected in the laboratory PT and PTT measurements (from reference #12 with permission).
An  additional  mechanism  in  which  the  activation  of  the  coagulation  cascade  can  take
place is through microparticles. Circulating microparticles are an area of intense research,
as increased levels  of  them were shown to be pro-coagulant,  even in the absence of  TF
expression [14-17].  These microparticles are tiny (<1 mm) membrane-bound vesicles and
express membrane antigens that reflect their cellular origin[18].  The concentration of cir‐
culating microparticles is increased during platelet activation, inflammation, or apoptosis.
Elevated  concentrations  of  microparticles  are  encountered  in  diseases  with  vascular  in‐
volvement and hypercoagulability such as disseminated intravascular coagulation, diabe‐
tes, and immune-mediated thrombosis [12].
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Anti-coagulation protein:
Thrombin also plays a crucial role in activating the inhibition of the coagulation cascade.
Following its activation thrombin binds to thombomodulin causing a conformational
change that activates the endothelial receptor of protein c, which in turns activates protein
C. The latter is bound to its cofactor protein s together this complex inactivates factor Va and
factor VIIIa of the intrinsic pathway, reducing substantially thrombin generation13. In addi‐
tion to protein c and protein s there is the tissue factor pathway inhibitor (TFPI) which is the
main inhibitor of the extrinsic pathway of coagulation, this protein inhibits the activity of
factor VIIa and factor Xa reducing by this thrombin generation by the extrinsic pathway. the
complex of protein z and Protein Z-dependent protease inhibitor (ZPI) inactivates factor Xa,
and can also directly inhibit factor XIa. However, by far the most active inhibitor of both fac‐
tor Xa and thrombin is antithrombin (AT) (previously known as antithrombin III). The AT
molecule binds to either thrombin or factor Xa and then complexes with vitronectin which
causes a conformational change that facilitates heparin binding. The resultant quaternary
structure augments thrombin inactivation 1000-fold. The function of these anticoagulation
protein is essential for maintaining the homeostasis between coagulation and adequate
blood flow in the vascular tree, and deficiency in these protein is associated with increase
risk for thromboembolic diseases and other complications.
Fibrinolysis factors and inhibitors: The process of fibrinolysis (i.e., clot lysis) is also crucial
to the prevention of thrombosis (Figure 4). Fibrin is degraded to its degradation products
(FDPs) by plasmin [19], that is generated from plasminogen by the action of tissue-type
plasminogen activator (tPA) embedded in fibrin. This process is accelerated when plasmino‐
gen itself is bound to fibrin. Endothelial cells produce a second plasminogen activator,
urokinase-type plasminogen activator (uPA). The latter’s activation requires high molecular
weight kininogen, kallikrein, and plasmin. This helps explain why deficiency of the former
two ‘‘intrinsic pathway’’ clotting factors (ie, activators of factor XI) paradoxically lead to
thrombosis and not bleeding.
There are series of inhibitors of premature fibrinolysis and, thus, hemorrhage. Plasmin is
directly inhibited by a2-plasmin inhibitor. This inhibitor is also bound to the fibrin clot where
it is positioned to prevent premature fibrinolysis. Type-1 plasminogen activator inhibitor
(PAI-1) is synthesized by endothelial cells and platelets in response to thrombin binding to
(protease activated receptor) PARs. In pregnancy, the decidua is a rich source of PAI-1, while
the placenta produces PAI-1 and PAI -2, and serve as the primary source for the latter [20,21].
In the initial stages of platelet plug and fibrin clot formation, endothelial cells release PAI-1
but after a delay, endothelial cells release tPA and uPA to promote fibrinolysis.
Thrombin-activatable fibrinolysis inhibitor (TAFI) is another antifibrinolytic factor which acts
by cleaving the C-terminal lysine in fibrin, to render it resistant to cleavage by plasmin [22,23].
Levels of TAFI are increased in the third trimester [23]. Interestingly, TAFI is also activated by
the thrombin-thrombomodulin complex, once again implicating thrombin as the ultimate
arbiter of hemostasis. The fibrinolytic system can influence coagulation in several ways. For
example, FDPs inhibit thrombin action, a major source of hemorrhage in disseminated
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intravascular coagulation. In addition, PAI-1 bounded to vitronectin and also to heparin can
directly inhibit thrombin and factor Xa activity [5,24].
Figure 4. Fibrinolysis factors and inhibitors. The following scheme shows the process of fibrin degradation and plas‐
min generation (from reference #5 with permission).
3. Pregnancy associated changes in the hemostatic system
Pregnancy is a challenging time period for the hemostatic system. The demands from this
system changes in different sites and are somewhat contradictory. The formation of the
placental bed in which the maternal blood is running outside the maternal vessels necessitate
the mother to address two challenges, the first one is to protect herself from a life threatening
bleeding, and the second is to enable a continues blood flow through the placental bed outside
the maternal blood vessels without activating the coagulation cascade. These challenges have
been addressed by the formation of three compartments: 1) The maternal compartment which
becomes adaptive and pro-coagulant to prevent severe bleeding during delivery; 2) The fetus
that develops his coagulation system during gestation while floating in the pro-coagulant
amniotic fluid; and 3) The maternal fetal interface of which the intervillous space is hypocoa‐
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gulated in order to ensure the extravascular laminar flow of maternal blood and the maternal
decidua is rich with tissue factor to prevent bleeding.
During gestation, changes in the coagulation system are considered to be adaptive to prevent
hemorrhage at the time of delivery [25-29]. Indeed, normal pregnancy has been associated with
excessive maternal thrombin generation [28,30] and a tendency for platelets to aggregate in
response to agonists [31,32] (TABLE 1). Pregnancy is accompanied by 2 to 3-fold increase in
fibrinogen concentrations and 20% to 1000% increase in factors VII, VIII, IX, X, and XII, all of
which peak at term [33]. The concentrations of vWF increase up to 400% by term [33]. By
contrast, those of pro-thrombin and factor V remain unchanged while the concentrations of
factors XIII and XI decline modestly[34]. Indeed there is evidence of chronic low-level thrombin
and fibrin generation throughout normal pregnancy as indicated by enhanced concentrations
of pro-thrombin fragment 1.2, thrombin-antithrombin (TAT III) complexes, and soluble fibrin
polymers[23]. Free protein S concentration declines significantly (up to 55%) during pregnancy
due to increased circulating complement 4B-binding protein its molecular carrier. Protein S
nadir at delivery and this reduction is exacerbated by cesarean delivery and infection [33,35].
As a consequence, pregnancy is associated with an increase in resistance to activated protein
C [23,33]. The concentrations of PAI-1 increase by 3 to 4-folds during pregnancy while plasma
PAI-2 values, which are negligible before pregnancy reach concentrations of 160 mg/L at
delivery [33]. Thus, pregnancy is associated with increased clotting potential, as well as
decreased anticoagulant properties, and fibrinolysis [5]. Therefore, it can be defined as a
prothrombotic state.
Increased Decreased No change
Systemic changes Procoagulant factors I,V,VII,VIII,IX,X XI
Anticoagulant factors Soluble TM PS
Adhesive proteins vWF
Fibrinolytic proteins PAI-1,PAI-2 t-PA TAFI
Microparticles and APLA MP APLA
Local placental changes TF TFPI
Table 1. Hemostatic changes in pregnancy [42].
In contrast to the maternal circulation and the decidua, the establishment of the uteroplacental
circulation challenges the hemostatic system. Indeed, fibrin deposition sites were identified in
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decidual veins at sites of trophoblast invasion, where villi are implanted into veins [36].
Compared with endothelial vasculature, the trophoblasts lining decidual spiral arteries have
a reduced capacity to lyse fibrin, and recent studies have shown that this is caused by high
concentrations of plasminogen activator inhibitors [37] that affects it fybrinolytic capabilities.
In addition, perivascular decidualized human endometrial stromal cells are ideally positioned
to prevent postimplantation haemorrhage during endovascular trophoblast invasion by
expressing TF, which is a primary cellular mediator of hemostasis [38,39]. In vivo and in vitro
studies have demonstrated that estradiol (E2) enhances TF expression during progesterone
induced decidualization. It was demonstrated that paracrine factors, such as endothelial
growth factor (EGF) are involved with steroid-enhancing TF expression in decidualized
human endometrial stromal cells through the EGF receptor [40]. The trophoblast and the
placenta have distinct anticoagulation properties that aimed on one hand to prevent bleeding
and on the other hand to allow laminar flow of maternal blood through the intervillous space
[41,42]. Accumulating evidence suggest that the trophoblast acquires properties of vascular
epithelium and expresses coagulation inhibitors such as tissue factor pathway inhibitor
2[43-45] (also known as placental protein 5 [46,47]), heparin co-factor II, dermatan sulfate [48,
49], and thrombomodulin [50-53] as well as pro-coagulant proteins such as tissue factor [38,54].
Moreover, a knockout mouse model for the endothelial receptor of protein C was lethal in-
utero and the embryos died on the 10.5 day of gestation, and fibrin deposition was found
around their giant trophoblast cells of these embryos [55]. Moreover, a recent report demon‐
strated that the placenta is an extra-hepatic source of the anti-coagulant proteins including
protein C, protein S, as well as protein Z, and their expression is constitutive irrespective of
obstetrical conditions [85].
4. The hemostatic system and preterm parturition
The involvement of the hemostatic system in the pathophysiology of preterm parturition is
becoming more and more apparent. Indeed, changes in maternal and fetal gens, abnormal
placental vascular finding and increased thrombin generation in the maternal circulation were
all reported in association with preterm parturition.
Genetic studies: During parturition there is remodeling of the extra cellular matrix of the
uterine cervix. Recently increased expression of the tissue type plasminogen activator gene
was reported during labor at term [56]. This finding was supported by the role of plasminogen
activation in the remodeling of the extracellular matrix in human amnion, chorio-decidua, and
placenta during and after labor [57]. Moreover, in a genetic association study that tested
maternal and fetal genes in women with preterm labor reported this gene to be highly express
in fetuses of Hispanic patients who delivered preterm.
Single nucleotide polymorphisms of the coagulation genes are associated with increased risk
for preterm birth. Indeed, in a study that aimed to identify the impact of genetic polymor‐
phisms with pro-thrombotic and anti-thrombotic effects on the occurrence of preterm birth in
a large cohort of very-low-birth-weight (VLBW)-infants and their mothers, and term-born-
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infants and their mothers, maternal factor VII-121del/ins and the infant's factor VII-121del/ins
polymorphisms were more frequent in the group of singleton VLBW and their mothers.
Furthermore, the frequency of the factor XIII-Val34Leu polymorphism was significantly lower
in singleton VLBW than in term infant controls; and in a multivariate regression analysis,
previous preterm delivery, the maternal carrier status of the factor-VII-121del/ins polymor‐
phism (OR=1.7, 95% CI: 1.12-2.5, p=0.007) and the lower frequency of infant's factor-XIII-
Val34Leu polymorphism (OR=0.53; 95% CI: 0.29-0.96; p=0.038) were found to be independently
associated with preterm delivery [58]. The association between Polymorphisms in factor VII
and preterm birth was also reported among Caucasian in the USA. This study included
maternal and fetal DNA from 370 patients. For maternal data the strongest associations were
found in genes in the complement-coagulation pathway related to decidual hemorrhage in
preterm birth. In this pathway 3 of 6 genes examined had SNPs significantly associated with
preterm birth, including factor V, factor VII, and tissue plasminogen activator. The single
strongest effect was observed in tPA marker rs879293 with a significant allelic and genotypic
association with preterm delivery (OR- 2.80, CI 1.77–4.44, for a recessive model). Finally,
exploratory multi-locus analyses in the complement and coagulation pathway were performed
and revealed a potentially significant interaction between a marker in Factor V (rs2187952) and
Factor VII (rs3211719) (p<0.001); the authors concluded that "These results support a role for
genes in both the coagulation and inflammation pathways, and potentially different maternal
and fetal genetic risks for preterm birth"[59].
Collectively the evidence brought here suggest that genetic polymorphism of the coagulation
genes may predispose a subset of women to an increased risk for preterm birth. What is the
role of gene environmental interaction and in what mechanisms these polymorphisms of the
coagulation genes affect the risk for preterm parturition are still unknown and are an area of
future research.
Changes in maternal circulation: Increased thrombin generation in the maternal circulation,
above that reported during normal pregnancy, has been reported in all the great obstetrical
syndromes including preeclampsia [60-66], fetal growth restriction [61,62,67,68], fetal death
[69], preterm labor (PTL) [30,70], and preterm PROM [30,69,71]. There are several possible
explanations for the increased thrombin generation reported in women with preterm partu‐
rition: 1) increased activation of coagulation cascade in the maternal circulation due to
pathological processes including bleeding or inflammation; and 2) depletion of anticoagula‐
tion proteins that subsequently leads to increased thrombin generation.
Increased activation of the coagulation cascade among women with preterm parturition is well
supported by the current literature. Indeed, women with preterm PROM and preterm labor
have a higher median maternal plasma concentration of thrombin-anti-thrombin (TAT) III
complexes [30,70]. In addition, in women with preterm labor elevated maternal plasma TAT
III concentration was associated with a higher chance to deliver within <7 days from admission
[69] (figure 5, and figure 6). Median maternal plasma Tissue factor, concentration is higher in
women with preterm PROM, but not in those with PTL, than in those with normal pregnancies
[72]. Nevertheless, women with preterm labor as well as those with preterm PROM had both
increased tissue factor activity in comparison to normal pregnant women.
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Figure 5. Thrombin–antithrombin III (TAT) levels in control patients, patients with preterm labor who delivered within
3 weeks, and patients with preterm labor who delivered after 3 weeks. Open diamonds, Mean levels; black error bars,
SD. *P <.05, Student-Newman-Keuls method (from reference #70 with permission).
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 Figure 6. Maternal plasma TAT III concentration in women with preterm labor (PTL) and those with a Normal preg‐
nancy (from reference #30 with permission).
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The activation of the coagulation system in the placental and maternal compartment of patients
with preterm parturition can result from the following underlying mechanisms: 1(decidual
hemorrhage that leads to a retro-placental clot formation [73]; 2) intra-amniotic infection which
can induce decidual bleeding and sub-clinical abruption [74], as well as increased intra-
amniotic TAT complexes [69]; and 3) an increased maternal systemic inflammatory response
[75] that may activate the extrinsic pathway of coagulation due to the expression and release
of tissue factor (TF) by activated monocytes [76]. These mechanisms result in an increased
thrombin generation, which has been associated with the following: 1) stimulation of decidual
cell secretion of matrix metalloproteinase (MMP) (i.e. MMP-1 and MMP-3) that can degrade
the extracellular matrix of the chorioamniotic membranes [77,78](as is in preterm PROM); and
2) myometrial activation and uterine contractions generation that may lead to preterm labor
with or without rupture of membranes and a subsequent preterm delivery [70,79,80]. While
thrombin is generated as a consequence of activation of the coagulation cascade, TF, the most
powerful natural pro-coagulant, is abundant in the uterine decidua in the normal state [81,82],
as part of an efficient hemostatic mechanism in the uterine wall, which is activated in the course
of normal pregnancy during implantation[83] and after delivery[84]. However, this hemostatic
mechanism may also be activated due to pathological decidual bleeding in pregnancies
complicated by placental abruption [73,85] and intra-amniotic infection [74].
A novel mechanism that may lead to an increased thrombin generation in women with preterm
parturition is depleted or insufficient anticoagulant proteins concentration. Indeed, women
with preterm labor without intra-amniotic infection or inflammation and those with vaginal
bleeding who delivered preterm had a lower median maternal plasma protein Z, a co-factor
that participate in the inhibition of factor Xa, concentration than women with normal preg‐
nancy and those with vaginal bleeding who delivered at term [86]. Moreover, both patients
with preterm labor and preterm PROM had a lower median maternal plasma concentration
of total tissue factor pathway inhibitor (TFPI), the main physiological inhibitor of the TF
pathway, regardless of the presence of infection or gestational age at delivery. These obser‐
vations suggest that the increased thrombin generation observed among these patients may
derive not only from an increased activation of the hemostatic system, but also from insuffi‐
cient anti-coagulation. The latter can be due to either low concentrations of the anticoagulant
proteins, or as a result of an abnormal balance between coagulation factors and their inhibitors.
The overall balance between the concentration and activity of the coagulation factors and the
anti-coagulation proteins is one of the determining factors of thrombin generation. In the
normal state, the immunoreactive concentrations of TFPI in the plasma are 500 to 1000 times
higher than that of TF [87], suggesting that an excess of anti-coagulant proteins closely controls
the coagulation cascade activity [87]. Although preterm labor was not associated with a
significant change in the median maternal plasma tissue factor concentration, the TFPI/TF ratio
was lower than that of normal pregnant women, mainly due to decreased TFPI concentrations.
Along with the reports that patients with preterm PROM [72], as well as those with pree‐
clampsia [88], have a lower median maternal plasma TFPI/TF ratio than that of normal
pregnant women. The lower TFPI/TF ratio in patients with preeclampsia occurs despite the
increase in the median maternal plasma TFPI concentration observed in these patients. This
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suggests that the balance between TF and its natural inhibitor may better reflect the overall
activity of the TF pathway of coagulation, than the individual concentrations of TF or TFPI.
Collectively, these observations suggest that our attention should be focused not only on the
coagulation protein but also on their inhibitors since an imbalance between them may
contribute to increased thrombin generation leading to the activation of preterm parturition.
Inflammation is a major process in term and pre term parturition. In recent years it has become
apparent that tight and reciprocal interactions exist between coagulation and inflammation
[90]. Originally, much attention was given to mechanisms by which inflammatory mediators,
most notably cytokines, can activate coagulation. More recent investigations have revealed
that, in turn, mediators involved in the regulation of coagulation and anticoagulation have
major effects on the inflammatory processes.
Inflammation elicits coagulation primarily by activating the tissue factor pathway [89] and the
generation of thrombin and fibrin. The pivotal role of tissue factor in activation of coagulation
during a systemic inflammatory response syndrome, such as produced by endotoxemia or
severe sepsis, is well established, and attenuation of the activation of the tissue factor/factor
VIIa pathway in endotoxemic humans and chimpanzees and in bacteremic baboons abrogated
the activation of the common pathway of coagulation [90-92] and decreased the morbidity
associated with these systemic inflammatory conditions.
During preterm PROM and preterm labor, there is a moderate maternal systemic inflam‐
mation that results in monocyte and granulocyte activation [75]. Activated monocytes ex‐
press  TF  on  their  membrane  [93-97]  and  shed  micro-particles  containing  TF  into  the
plasma [93].  In addition,  the lack of  association between intra-amniotic  infection/inflam‐
mation, as well as the placental histologic findings and median maternal plasma concen‐
trations  of  TF  and  TFPI,  suggest  that  the  pro-coagulant  changes  observed  in  patients
with preterm PROM may be due to a systemic rather than a local (i.e.  placental,  intrau‐
terine) inflammatory process.
Moreover, preterm PROM is associated with an increased activation of the decidual compo‐
nent of the common pathway of parturition [98]. Thus, in pregnancies complicated by
abnormal placentation or intrauterine infection, decidual bleeding may lead to a higher
expression of TF and activation of the coagulation cascade, resulting in increased thrombin
generation. The latter has uterotonic properties that may generate uterine contractions that
could initiate labor [70,79,80]. Moreover, thrombin can mediate the activation of MMP-1 [78],
MMP-3 [77], and MMP-9[99] that can digest components of the extracellular matrix, weaken
the chorioamniotic membranes and predispose to preterm PROM.
The mechanisms described above are localized to the maternal-fetal interface. The lack of
association between median maternal plasma TF concentrations and the presence of intra-
amniotic infection/inflammation or vaginal bleeding in patients with preterm PROM suggest
that the systemic maternal inflammatory response during preterm PROM[75] may contribute
the increase median maternal plasma TF concentration in these patients regardless to the
presence of infection or inflammation in the amniotic cavity or the occurrence of vaginal
bleeding [100].
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In addition to the maternal circulation intra-amniotic infection and/or inflammation is
associated with an increased amniotic fluid TAT III complexes (figure 7). This is important
since it represent an increased thrombin generation in the amniotic cavity during infection and
or inflammation that may contribute to uterine contractility and the development of preterm
birth [99]. Of interest, elevated intra-amniotic TAT III concentrations were associated with a
shorter amniocentesis to delivery interval and an earlier gestational age at delivery only
inpatients with preterm labor without intra-amniotic infection or inflammation [99]. This
observation suggest that in a subset of patients with preterm labor activation of the coagulation
system can generate preterm parturition and delivery; while in those with intra-amniotic
infection and or inflammation the activation of the coagulation and thrombin generation is a
byproduct of the inflammatory process leading to preterm birth.
Figure 7. The effect of amniotic fluid thrombin-antithrombin (TAT) III concentrations on gestational age at delivery
(from reference #69 with permission)
5. Placental vascular changes in women with preterm parturition
Accumulating evidence from studies of the placenta [101,102], uterine artery Doppler scans
[103], and animal experiments [104], suggest a role for uteroplacental ischemia in preterm birth.
Indeed, Arias et al reported that about 20% of the placentas of patients who delivered preterm
following preterm labor or preterm PROM had vascular lesions [105].
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The invasion of trophoblast cells into the decidual and myometrial segments of the spiral
arteries is a key point of normal placentation. This process results in reversible changes of the
normal spiral arteries wall architecture [106]. The ‘‘disappearance of the normal muscular and
elastic structures of the arteries and their replacement by fibrinoid material in which tropho‐
blast cells are embedded’’ was originally termed physiologic transformation by Brosens et al
in 1967. This process progressively remodeled, starting from the end of the first trimester
onward, the uterine spiral arteries to form dilated conduits lacking maternal vasomotor
control, ensuring the delivery of a constant supply of blood to the maternal-fetal interface at
an optimal velocity for nutrient exchange [107]. Notably, several coagulation components,
such as TF and thrombomodulin, are involved not only in hemostasis but also with placental
blood vessel differentiation [38,42], affecting thereby the generation of different pathological
condition affecting pregnancy and parturition; A higher rate of failure of transformation of the
spiral arteries was reported in placentas of patients with preterm labor and preterm PROM
than in those of normal pregnant women. This lesion has been implicated in the increased
vascular resistance in the placental bed and the reduction of blood flow to the intervillous
space [108,109], this is considered as a marker for defective placentation. Failure of transfor‐
mation of the spiral artery was first reported in women with preeclampsia [110]. Indeed, the
extent of this lesion in placenta of women with preeclampsia is more extensive than what is
detected in women with preterm labor or preterm PROM [111-113], suggesting when extensive
failure of physiologic transformation is present, narrowed uteroplacental arteries predispose
to reduced perfusion of the intervillous space, ischemia, and compensatory maternal hyper‐
tension. If these lesions are less extensive, the degree of ischemia may be insufficient to induce
maternal hypertension, but may predispose to preterm labor/preterm delivery by itself or in
association with other pathologic processes, such as intrauterine infection. A report that
support the concept that clinical presentation is somewhat reflecting the extent of the disease
is the study by Espinoza et al who found that women with an episode of preterm labor who
delivered at term had a higher rate of SGA neonates and increased frequency of placental
vascular lesions in comparison to those with preterm labor who delivered preterm [114]. This
finding suggests that in some cases the vascular lesions that lead to development of preterm
labor is not severe enough to cause preterm birth, however the "price" for the continuum of
the pregnancy to term is decrease fetal growth.
6. The future — Hemostatic markers for preterm parturition?
In light of the association between maternal plasma TAT III concentrations in women with
preterm labor and preterm birth within a week; and the association between amniotic fluid
TAT III concentrations, the interval from amniocentesis to delivery, and gestational age at
delivery. The question of the role of hemostatic markers as predictors for preterm birth is
relevant. A preliminary report by Vidaeff et al found that increased concentrations of amniotic
fluid TAT III concentration during mid-trimester amniocentesis of asymptomatic patients is
associated with subsequent preterm delivery [115]. Aside the amniotic fluid new assays that
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study the thrombin generation potential in maternal blood may offer similar answer in less
invasive methods [116].
7. Conclusions
The understanding of the homeostasis system and coagulation process is crucial for under‐
standing the physiological and pathological parturition. The significant impact of placentation
abnormalities caused by those same changes in the haemostatic system, on maternal and fetal
wellbeing is yet to be studied.
The aim of this chapter was to provide a window to the complexity of the normal homeostasis
and pregnancy and a view of the different pathological conditions that may emerge during
parturition. The inflammation as well as the coagulation and placental implantation are all
part of the total picture of parturition.
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